The role of autologous natural killer cells in chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 387-399

  Pierson, Bryce A ^a,b   Miller, Jeffrey S ^b  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autologous NK cells; Chronic myeloid leukemia; CML

Indexed keywords

CD34 ANTIGEN; INTERLEUKIN 2;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0031474337     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058306     Document Type: Review

References (85)

1. Dube, I. D., Gupta, C. M., Kalousek, D. K., Eaves, C. J. and Eaves, A. C. (1984). Cytogenetic studies of early myeloid progenitor compartments in Ph1 positive chronic myelogenous leukemia. Br J Haematol, 56, 633.
2. Bernstein, R. (1988). Cytogenetics of chronic myelogenous leukemia. Semin Hematol, 25, 20.
3. DeKlein, A., Van Kessel, A. G., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J. and Stephenson, J. R. (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature, 300, 765.
4. Cashman, J., Eaves, A. C. and Eaves, C. J. (1985). Regulated proliferation of primitive hematopoietic progenitors in long-term human marrow cultures. Blood, 66, 1002.
5. Verfaillie, C., Blakolmer, K. and McGlave, P. (1990). Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere to selectively to irradiated bone marrow stroma. J Exp Med, 172, 509-520.
6. Gordon, M. Y., Dowding, C. R., Riley, M. P., Goldman, J. P. and Greaves, M. F. (1984). Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myelogenous leukemia. Nature, 328, 342.
7. Verfaillie, C. M., McCarthy, J. B. and McGlave, P. B. (1992). Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest, 90, 1232.
8. Eaves, A. C., Cashman, J. D., Gaboury, L. A., Kalousek, D. K. and Eaves, C. J. (1986). Unregulated proliferation of primitive chronic myelogenous leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA. 83, 5306.
9. Bhatia, R., McGlave, P. B., Dewald, G. W., Blazar, B. R. and Verfaillie, C. M. (1995). Abnormal function of the bone marrow microenvironment in chronic myelogenous Iwukemia: Role of malignant stromal macrophages. Blood. 85, 3636-3645.
10. Pawelec, G., Schmidt, H., Schneider, E., Buhring, H. J. and Ehninger, G. (1988). Cellular immunological defects of chronic myelogenous leukaemics: Partial dependence on busulphan therapy. Cancer Immunol Immunother, 27, 89-94.
11. Gibson, F. M., Malkovska, V., Myint, A. A., Meager, A. and Gordon-Smith, E. C. (1991). Mechanism of suppression of normal hematopoietic activity by lymphokine-activated killer cells and their products, Exp Hematol, 19, 659-663.
12. Miller, S. C. and Christopher, F. L. (1989). Altered production and renewal of natural killer cells in B-lymphocyte-deficient CBA/N mice. Nat Immun Cell Growth Reg, 8, 245-254.
13. Talpaz, M., Kantajian, H. M., Kurzrock, R., Trujillo, J. M. and Gutterman, J. U. (1991). Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients. Ann Intern Med. 114, 532-538.
14. Ellis, T., McKenzie, R., Simms, P., Helfrich, B. and Fisher, R. (1989). Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J Immunol, 143, 4282.
15. Dabholkar, M., Advani, S., Tatake, R. and Gangal, S. (1986). Natural and antibody-dependent cellular cytotoxicity in chronic myelogenous leukemia patients in remision. Leukemia Research, 10, 203-209.
16. Klingemann, H. G., Grigg, A. P., Wilkie-Boyd, K., Barnett, M. J., Eaves, A. C., Reece, D. E., Shepard, J. D. and Phillips, G. L. (1991). Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood, 78, 3306-3311.
17. Upadhyaya, G., Guba, S. C., Sih, S. A., Feinberg, A. P., M. T., Kantarjian, H. M., Deisseroth, A. B. and Emerson, S. G. (1991). Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 88, 2131-2136.
18. Bhatia, R., Wayner, E. A., McGlave, P. B. and Verfaillie, C. M. (1994). Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest. 94, 384.
19. Bhatia, R., McGlave, P. B. and Verfaillie, C. M. (1995). Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors: Role of MIP-1α. J Clin Invest., 96, 931-939.
20. Bhatia, R., McCarthy, J. B. and Verfaillie, C. M. (1996). Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood, 87, 3883-3891.
21. Miller, J. S. and McGlave, P. B. (1993). Therapy for chronic myelogenous leukemia with marrow transplantation. Curr Opin Oncol, 5, 262-269.
22. Marmont, A. M., Horowitz, M. M., Gale, R. P., Sobocinski, K., Ash, R. C., van Bekkum, D. W., Champlin, R. E., Dicke, K. A., Goldman, J. M., Good, R. A., Herzig, R. H., Hong, R., Masaoka, T., Rimm, A. A., Ringden, O., Speck, B., Wiener, R. S. and Bortin, M. M. (1991). T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120.
23. Jiang, Y. Z., Kanfer, E. J., MacDonald, D., Cullis, J. O., Goldman, J. M. and Barrett, A. J. (1991). Graft-versusleukemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukemia cells. Bone Marrow Transplant. 8, 253-258.
24. Mackinnon, S., Bungey, J., Chase, A., Paulsen, W., Hows, J. M. and Goldman, J. M. (1991). Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukemia who relapse following bone marrow transplantation. Brit J of Haematology, 77, 60-65.
25. Mackinnon, S., Hows, J. M. and Goldman, J. M. (1990). Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood, 76, 2037-2045.
26. Enright, H., Davies, S. M., DeFor, T., Shu, X., Weisdorf, D., Miller, W., Ramsay, N. K. C., Arthur, D., Verfaillie, C., Miller, J., Kersey, J. and McGlave, P. (1996). Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood, 88, 714-720.
27. Champlin, R. (1993). Allogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia. Leukemia, 7, 1084-1086.
28. Kolb, H. J., Schattenberg, A., Goldman, J. M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E. and Ansari, H. (1995). Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
29. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L., Collins, N. H., Boulad, F., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Kernan, N. A., Small, T. N., Young, J. W. and O'Reilly, R. J. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graftversus-host disease. Blood, 86, 1261-1268.
30. Verfaillie, C. M., Bhatia, R., Miller, W., Mortari, F., Roy, V., Burger, S., McCullough, J., Stieglbauer, K., Dewald, G., Heimfeld, S., Miller, J. S. and McGlave, P. B. (1996). BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most earlychronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood, 87, 4470-4479.
31. Miller, J. S., Verfaillie, C. and McGlave, P. B. (1991). Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors. Blood, 77, 2389-2395.
32. Miller, J. S., Oelkers, S., Verfaillie, C. and McGlave, P. B. (1992). Role of monocytes in the expansion of human activated natural killer cells. Blood, 80, 2221-2229.
33. Mule, J. J., Shu, S. and Rosenberg, S. A. (1985). The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol, 135, 646-652.
34. Hercend, T., Farace, F., Baume, D., Charpentier, F., Droz, J., Triebel, F. and Escudier, B. (1990). Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: A feasibility trial in metastatic renal cell carcinoma. J Biol Resp Mod, 9, 546-555.
35. Melder, R. J., Balachandran, R., Rinaldo, C. R., Gupta, P., Whiteside, T. L. and Herberman, R. B. (1990). Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells. AIDS Res Hum Retroviruses, 6, 1011-1015.
36. Robertson, M. J. and Ritz, J. (1990). Biology and clinical relevance of human natural killer cells, Blood, 76, 2421-2438.
37. Rosenberg, S., Lotze, M., Muul, L., Leitman, S., Chang, A., Ettinghausen, S., Matory, Y., Skibber, J., Shiloni, E., Vetto, J., Siepp, C., Simpson, C. and Reichert, C. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N Engt J of Med, 313, 1485-1492.
38. Schmidt, R. E. (1989). Natural Killer Cells: Biology and Clinical Application. The 6th International Natural Killer Cell Workshop. New York: Goslar.
39. Trinchieri, G. (1989). Biology of Natural Killer Cells. Advances in Immunology, 47, 187-375.
40. Pierson, B. A., Miller, J. S., Verfaillie, C., McGlave, P. B. and Hu, W. S. (1994). Population dynamics of human activated natural killer cells in culture. Bioengineering and Biotechnology, 43, 685-692.
41. Rosenberg, S., Lotze, M., Muul, L., Chang, A., Avis, F., Leitman, S., Lineham, W., Robertson, C., Lee, R., Rubin, J., Siepp, C., Simpson, C. and White, D. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med, 316, 889-897.
42. Whiteside, T. L., Ernstoff, M. S., Nair, S., Kirkwood, J. M. and Herberman, R. B. (1990). In vitro generation and in vivo effects of adherent lymphokine-activated killer cells and IL-2 in patients with solid tumors. In Natural Killer Cells: Biology and Clinical Significance, edited by RE Schmidt, p 293 Basel, Switzerland: Karger.
43. Lotzova, E. (1988). Role of natural killer cells in defense against leukemia: Therapeutic considerations. Nat Immun Cell Growth Regul, 7, 170-179.
44. Lotzova, E., Savary, C. A. and Herberman, R. B. (1987). Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. . Leukemia Research. 11, 1059-1066.
45. Savary, C. A. and Lotzova, E. (1989). Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias. Exp Hematol, 17, 183-187.
46. Verfaillie, C., Miller, W., Kay, N. and McGlave, P. B. (1989). Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood, 74, 793-797.
47. Grimm, E. A., Mazumder, A., Zhang, H. Z. and Rosenberg, S. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med, 155, 1823-1841.
48. Cervantes, F., Pierson, B. A., McGlave, P. B., Verfaillie, C. M. and Miller, J. S. (1996). Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood, 87, 2476-2485.
49. Pawelec, G., Da Silva, P., Max, H., Kalbacher, H., Schmidt, H., Bruserud, O., Zugel, U., Baier, W., Rehbein, A. and Pohla, H. (1995). Relative roles of natural killer- and T-cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-α. Leukemia and Lymphoma, 18, 471-478.
50. Schwarz, R. E., Felgar, R. E. and Hiserodt, J. C. (1990). Successful adoptive immunotherapy of established lung and liver metastases with highly purified IL-2 activated natural killer cells (A-LAK cells). In Natural Killer Cells: Biology and Clinical Significance, edited by RE Schmidt, p 303-306. Basel, Switzerland: Karger.
51. Herberman, R. B., Hiserodt, J., Vujanovic, N., Balch, C., Lotzova, E., Bohlius, R., Golub, S., Lanier, L. L., Phillips, J. H., Riccardi, C., Ritz, J., Santoni, A., Schmidt, R. E. and Uchida, A. (1987). Most lymphokine-activated killer (LAK) activity mediated by blood and splenic lymphocytes is attributable to stimulation of natural killer cells by interleukin-2. Immunol Today, 8, 178-181.
52. van den Brink, M. R. M., Hunt, L. E. and Hiserodt, J. C. (1990). In vivo treatment with monoclonal antibody 3. 2. 3 selectively eliminates natural killer cells in rats. In Natural killer cells: Biology and Clinical Significance, edited by RE Schmidt, p. 307, Basel, Switzerland: Karger.
53. Jonas, D., Lubbert, M., Kawasaki, E. S., Henke, M., Brass, K. J., Mertelsmann, R. and Herrmann, F. (1992). Clonal analysis of bcr-abl rearrangement in T-lymphocytes from patients with chronic myelogenous leukemia. Blood, 79, 1017-1023.
54. Torlakovic, E., Litz, C. E., McClure, J. S. and Brunning, R. D. (1994). Direct detection of the Philadelphia chromosome in CD20-positive lymphocytes in chronic myeloid leukemia by tri-colorimmunophenotyping/FISH. Leukemia. 8, 1940-1943.
55. Vujanovic, N. L., Herberman, R. B., Maghazachi, A. A. and Hiserodt, J. C. (1988). Lymphokine-activated killer cells in rats. III. A simple method for purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J Erp Med, 167, 15-29.
56. Melder, R., Whiteside, T., Vujanovic, N., Hiserodt, J, and Herberman, R. (1988). Human adherent lymphokine-activated killer (A-LAK) cells: A new approach to generating antitumor effectors for adoptive immunotherapy. Cancer Res, 48, 3461-3469.
57. Verfaillie, C., Kay, N., Miller, W. and McGlave, P. B. (1990). Diminished A-LAK cytotoxicity and proliferation accompanies disease progression in chronic myelogenous leukemia. Blood, 76, 401-108.
58. Silla, L. M., Pincus, S. M., Locker, J. D., Glover, J., Elder, E. M., Donnenberg, A. D., Nardi, N. B., Bryant, J., Ball, E. D. and Whiteside, T. L. (1996). Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of bcr/abl positive targets. Brit J Haematol, 93, 375-385.
59. Warzynski, C., White, C., Golightly, M. G., Steingart, R., Otto, R. N., Podgurski, A. E., Johnson, M. L., Glynn, P., Smith, D. E. (1989). Natural killer lymphocyte blast crisis of chronic myelogenous leukemia. Amer J Hematol, 32, 279-286.
60. - primitive progenitors in long-term bone marrow culture. Blood, 80, 2182-2187.
61. + NK progenitor. Blood. 83, 2594-2601.
62. Sitnicka, E., Hannson, M. (1992). Natural killer cell activity in human long-term bone marrow cultures: Effects of IL-2 and granulocyte-macrophage colony stimulating factor on progenitor cells. Immunol, 76, 292-298.
63. Pierson, B. A. Ex vivo expansion of human natural killer cells (NK) for adoptive immunotherapy., University of Minnesota, 1995
64. Pierson, B. A., Europa, A. F., Hu, W. S., Miller, J. S. (1996). Production of human natural killer cells for adoptive immunotherapy utilizing a computer-controlled stirred-tank bioreactor. J of Hemalother, 5, 475-483.
65. Pierson, B. A., Gupta, K., Hu, W. S., Miller, J. S. (1996). Human natural killer cell expansion is regulated by thrombospondin-mediated activation of TGF-β1 and independent accessory cell-derived contact and soluble factors. Blood, 87, 180-189.
66. Murphy-Ullrich, J. E., Schultz-Cherry, S., Hook, M. (1992). Transforming growth factor-β complexes with thrombospondin. Mol Biol Cell, 3, 181-188.
67. Schultz-Cherry, S., Murphy-Ullrich, J. E. (1993). Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol, 122, 923-932.
68. Schultz-Cherry, S., Ribeiro, S., Gentry, L., Murphy-Ullrich, J. E. (1994). Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem, 269, 26775-26782.
69. Schultz-Cherry, S., Lawler, J., Murphy-Ullrich, J. E. (1994). The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J Biol Chem, 269, 26783-26788.
70. Nagler, A., Lanier, L. L., Cwirla, S., Phillips, J. H. (1989). Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol, 143, 3183-3191.
71. Ellis, T. M., Fisher, R. I. (1989). Functional heterogeneity of Leu 19 "bright" + and Leu 19 "dim" + lymphokine-activated killer cells. J Immunol, 142, 2949-2954.
72. Nagler, A., Lanier, L. L., Phillips, J. H. (1990). Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med, 171, 1527-1533.
73. Robertson, M. J., Manley, T. J., Donahue, C., Levine, H., Ritz, (1993). Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol, 150, 1705-1714.
74. +dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli which recruit clonogenic NK, and exhibit decreased proliferation on a per cell basis. Blood, 88, 2279-2287.
75. Miller, J. S., Klingsporn, S., Lund, J., Perry, E. R, Verfaillie, C., McGlave, P. (1994). Large-scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplantation, 14, 555-562.
76. Fujimiya, Y., Bakke, A., Chang, W. C., Linker-Israeli, M., Udis, B., Horwitz, D., Pattengale, P. K. (1986). Natural killer cell immunodeficiency in patients with chronic myeloid leukemia I: Analysis of the deficit using the antibodies NKHI (leu-7) and B73.1. J Cancer, 37, 639-649.
77. Lotzova, E., Savary, C. A., Herberman, R. B. (1987). Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol, 138, 2718.
78. Pawelec, G., Schneider, E., Ehninger, G., Rehbein, A., Schmidt, H. (1989). Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-α (Wellferon). Cancer Immunol Immunother, 29, 63-66.
79. + natural killer cells after bone marrow transplantation. Blood, 79, 3239.
80. Laughlin, M., Loftus, J., Herzig, G. P., Caligiuri, T., Caligiuri, M. (1993). Natural killer (NK) activity following dose intensive chemotherapy. (Abstract). Blood, 82, 242a.
81. Reittie, J. E., Gottlieb, D., Heslop, H. E., Leger, O., Drexler. H. G., Hazelhurst, G., Hoobrand, A. V., Prentice, H. G., Brenner, M. K. (1989). Endogenously generated activated natural killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood, 73, 1351-1358.
82. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., Ritz, J. (1992). Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79, 517-526.
83. Miller, J. S., Tessmer-Tuck, J., Pierson, B. A., Weisdorf, D., McGlave, P., Blazar, B., Katsanis, E., Verfaillie, C., Lebkowski, J., Radford, J., Burns, L. (1997). Low-dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biology of Blood and Marrow Transplantation, (in press).
84. Miller, J. S., Tessmer-Tuck, J., Blake, N., Lund, J., Scott, A., Blazar, B. R., Orchard, P. J. (1997). Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer. Exp Hematol, (in press).
85. Pierson, B. A., McGlave,P. B., Hu, W. S., Miller, J. S. (1995). Natural killer cell proliferation is dependent on human serum and is markedly increased utilizing an enriched supplemented basal medium. J Hematotherapy, 4, 149-158.